Novartis perseveres with pelabresib
A new phase 3, Manifest-3, will start in April to support US filing.
ImmunityBio tries again in papillary bladder cancer
And the company says it won’t need to carry out another trial.
Pfizer trims its pan-KRAS efforts
The “next-gen” PF-07985045 is gone, but the group has another pan-KRAS shot.
Revolution shows its selective hand
The company will start three phase 3 trials of its G12D project this year.
Ebvallo gets a second US knockback
Things look grim for Atara, which had been relying on a milestone from Pierre Fabre.
CG Oncology gets an intermediate-risk bladder boost
Readout of the Pivot-006 trial is brought forward by nearly a year.
